Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 4

| *COMPLETE IF KNOWN* | |
|---|---|
| Application Number | 10/020,740 #4 |
| Filing Date | December 14, 2001 |
| First Named Inventor | R.K. Bakshi et al. |
| Group Art Unit | ~~To Be Assigned~~ 1624 |
| Examiner Name | ~~To Be Assigned~~ Coleman |
| Attorney Docket Number | 19526PR |

JC879 U.S. PTO 10/020740 12/14/01

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. | U.S. Patent Document Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | class | subclass | Date of Publication of Cited Document MM-DD-YYYY |
|---|---|---|---|---|---|---|---|
| BC | | 5,302,621 | | Kojima et al. | 514 | 284 | 04/12/1994 |
| BC | | 4,191,759 | | Johnston et al. | 424 | 242 | 03/04/1980 |
| BC | | 4,377,584 | | Rasmusson et al. | 424 | 258 | 03/22/1983 |
| BC | | 5,116,983 | | Bhattacharya et al. | 546 | 14 | 05/26/1992 |
| BC | | 5,304,562 | | Biollaz | 514 | 284 | 04/19/1994 |
| BC | | 4,760,071 | | Rasmusson et al. | 514 | 284 | 07/26/1988 |
| BC | | 5,151,429 | | Rasmusson et al. | 514 | 284 | 09/29/1992 |
| BC | | 5,565,467 | | Batchelor et al. | 514 | 284 | 10/15/1996 |
| BC | | 5,693,809 | | Durette et al. | 546 | 77 | 12/02/1997 |
| BC | | 5,696,266 | | Humphrey et al. | 546 | 77 | 12/09/1997 |
| BC | | 6,121,449 | | Panzeri et al. | 546 | 77 | 09/19/2000 |
| BC | | 5,547,957 | | Gormley et al. | 514 | 284 | 08/20/1996 |
| BC | | 5,872,126 | | Cukierski et al. | 514 | 284 | 02/16/1999 |
| BC | | 5,084,574 | | Bhattacharya et al. | 546 | 77 | 01/28/1992 |
| BC | | 5,693,810 | | Rasmusson et al. | 546 | 77 | 12/02/1997 |
| BC | | 5,817,802 | | Humphrey et al. | 540 | 77 | 10/06/1998 |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document Office | Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|---|---|---|---|---|---|---|
| BC | | PCT | WO 94/07861 | | Merck & Co., Inc. | 04/14/1994 |
| BC | | PCT | WO 92/16213 | | Merck & Co., Inc. | 10/01/1992 |
| BC | | EPO | 0 484 094 | | Sankyo Company Limited | 06/05/1992 |
| BC | | PCT | WO 95/07926 | | Glaxo Inc. | 03/25/1995 |
| ** BC | | EPO | 0 538 192 | | CIBA-GEIGY AG | 04/21/1993 |
| BC | | PCT | WO 95/07927 | | Glaxo Inc. | 03/23/2001 |
| BC | | PCT | WO 97/11702 | | Merck & Co., Inc. | 04/03/1997 |
| BC | | PCT | WO 94/15602 | | Merck & Co., Inc. | 07/21/1994 |
| BC | | PCT | WO 94/11385 | | Smith-Kline Beechan Corporation | 05/26/1994 |
| BC | | EPO | 0 004 949 A1 | | Merck & Co., Inc. | 04/12/1979 |

** structures only

| Examiner Signature | Brenda Coleman | Date Considered | Nov. 21, 2003 |
|---|---|---|---|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 2 of 4

| COMPLETE IF KNOWN | |
|---|---|
| Application Number | 10/020,740 |
| Filing Date | December 14, 2001 |
| First Named Inventor | Bakshi, R.K. et al. |
| Group Art Unit | ~~To Be Assigned~~ 1624 |
| Examiner Name | ~~To Be Assigned~~ Coleman |
| Attorney Docket Number | 19526PR |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. | U.S. Patent Document Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|---|---|---|---|---|---|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document Office | Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|---|---|---|---|---|---|---|
| BC | | EPO | 0 004 949 B1 | | Merk & Co., Inc. | 04/12/1979 |
| BC | | EPO | 0 655 459 A2 | | Merck & Co., Inc. | 11/13/1990 |
| ~~—~~ | ~~—~~ | ~~EPO~~ | ~~0 655 459 A2~~ duplicate | | ~~Merck & Co., Inc.~~ | ~~11/13/1990~~ |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| Examiner Signature | Brenda Coleman | Date Considered | Nov. 21, 2003 |
|---|---|---|---|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 4

| *COMPLETE IF KNOWN* | |
|---|---|
| **Application Number** | 10/020,740 |
| **Filing Date** | December 14, 2001 |
| **First Named Inventor** | R.K. Bakshi et al. |
| Group Art Unit | ~~To Be Assigned~~ 1624 |
| Examiner Name | ~~To Be Assigned~~ Coleman |
| Attorney Docket Number | 19526PR |

## OTHER NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. |
|---|---|---|
| | AA | ~~Bakshi et al., 4-aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5a-reductases. J. Med. Chem. 38 (1995), pp. 3189-3192~~ duplicate |
| BC | AB | Andriole et al., "Treatment with Finasteride Following Radical Prostatectormy for Prostate Cancer", Urology 45(3): 491-497 (1995) |
| BC | AC | Tsukamoto et al., "Chemoprevention of Rat Prostate Carcinogenesis by Use of Finasteride or Casodex", 87 J. Nat'l Cancer Inst., pp. 842-843 (1995) |
| BC | AD | Tolman et al., 5th Int'l Congress Hormones & Cancer Program and Abstract, Quebec City, Sept. 16-20, 1995, p.92, Abstract 48, "4-methyl-4-azateroid 17beta(N-aryl substituted)carboxamides: Potent antiandrogenic activity with 5a-reductase inhibition |
| BC | AE | Tolman et al., "4-Methyl-3-oxo-4-aza-5alpha-androst-1-en17beta-N-aryl-carboxamide: An approach to combined androgen blockade"; in press, expected to publish in March 1996 issue of J. Steroid Biochem & Molec. Bio |
| BC | AF | Bologna et al, "Antiandrogens and 5-alpha Reductase Inhibition of the Proliferation Rate in PC3 and DU145 Human Prostatic Cancer Cell Lines", 51(6) Curr. Ther. Res., pp. 799-813 (1992) |
| BC | AG | Denis, Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice. Prostate 27 (1995), pp. 223-240 |
| BC | AH | Bakshi et al., ACS Division of Medicinal Chemistry, 209th ACS Nat'l meeting Anaheim, CA, April 2-6, 1995, Abstract No. 011, "N-Phenyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamides as inhibitors of both human type 1 and type 2 5alpha-redutases |
| BC | AI | Rasmusson et al., J. Med. Chem., Vol. 29, pp. 2298-2315 (1986), "Azasteroids: Structure-activity relationships for inhibition of 5alpha-reductase and of androgen receptor binding." |
| BC | AJ | Liang et al., Endrocrinology, Vol. 117, pp. 571-579 (1985), "Species differences in prostatic steroid 5alpha-reductases of rat, dog, and human" |
| BC | AK | Bakshi, R.K., et al., "4-Aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5a-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5a-Reductase Inhibitory Potency.", J. Med. Chem., Vol. 38, No. 17, 1995 |
| BC | AL | Bakshi, et al., Additions and Corrections, J. of Med. Chem., Vol. 39, No. 5, p. 1192, 1996 |
| BC | AM | Mellin, T.N., et al., "Azateroids as Inhibitors of Testosterone 5a-Reductase In Mammalian Skin", J. of Steroid Biochem. and Molec. Bio., Vol. 44, No. 2, pp. 121-131, 1993 |
| BC | AN | Rasmusson, G.H., et al., "Azasteroids as Inhibitors of Rat Prostatic 5a-Reductase", J. of Med. Chem., Vol. 27, No. 12, pp. 1690-1701, 1984 |
| BC | AO | Zheng, Jinhong, et al., Chem. Abs., Vol. 122, No. 25, 1995 |

| Examiner Signature | Brenda Coleman | Date Considered | Nov. 21, 2003 |
|---|---|---|---|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 4 of 4

| COMPLETE IF KNOWN | |
|---|---|
| **Application Number** | 10/020,746 |
| **Filing Date** | December 14, 2001 |
| **First Named Inventor** | R.K. Bakshi et al. |
| Group Art Unit | ~~To Be Assigned~~ 1624 |
| Examiner Name | ~~To Be Assigned~~ Coleman |
| Attorney Docket Number | 19526PR |

## OTHER NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. |
|---|---|---|
| BC | AP | Kurata, H., et al., "Synthesis and Testosterone 5a-Reductase-Inhibitory Activity of 4-Aza-5a-androstane-17-caboxamide Compound with an Aromatic Moiety in the C-17 Carbamoyl Group", Chem. Pharm. Bull. Vol. 44(1), pp. 115-121 (1996) |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Examiner Signature | Brenda Coleman | Date Considered | Nov. 21, 2003 |
|---|---|---|---|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.